PIM-1 inhibition with AZD1208 to prevent osimertinib-induced resistance in EGFR-mutation positive non-small cell lung cancer

Abstract

Aim: The progression free survival of non-small cell lung cancer (NSCLC) patients has been doubled over the last years, but still single epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) lead to incomplete responses. Compensatory signaling pathways are activated upon single EGFR TKIs. We have shown that compounds, which inhibit these pathways, are synergistic with EGFR TKIs. Proviral integration site for Moloney murine leukemia virus (PIM) has been connected to cancer therapy resistance, being involved in receptor tyrosine kinase, signal transducer and activator of transcription 3 (STAT3) and interleukin-6 signaling. We hypothesized that combined PIM and EGFR inhibition may improve the upfront therapy of EGFR-mutation positive NSCLC.

Methods: We reviewed the literature on PIM kinases, and performed cell viability assays, gene expression analyses, and immunoblotting experiments to reveal the mechanisms of action of the PIM inhibitor (AZD1208) alone and combined with osimertinib in five EGFR-mutation positive NSCLC cell lines.

Results: Osimertinib alone induced the activation of signal transducer and activator of transcription 3 (STAT3) as well as other signaling nodes. Combined osimertinib and AZD1208 yielded moderate synergistic effects in all NSCLC cell lines investigated. Among the EGFR-mutation positive cell lines examined, the H1975 and PC9 cell lines had the highest PIM1 and STAT3 mRNA expression. The combination decreased the osimertinib-induced STAT3 phosphorylation.

Conclusion: This study provides a short review on PIM kinases, and shows our results of combined PIM and EGFR inhibition in EGFR-mutation positive NSCLC cell lines. The combination was moderately synergistic but decreased STAT3 phosphorylation, an important signaling node in therapy resistance.

Keywords

Non-small cell lung cancer / EGFR / PIM-1 / AZD1208 / tyrosine kinase inhibitors

References

[1] Sordella R,Haber DA.Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways..Science2004;305:1163-7

[2] Lazzara MJ,Chan R,Yaffe MB.Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations..Cancer Res2010;70:3843-50 PMCID:PMC2862125

[3] Karachaliou N,Bracht JWP.EGFR first- and second-generation TKIs-there is still place for them in EGFR-mutant NSCLC patients..Transl Cancer Res2018;

[4] Rosell R,Gervais R,Massuti B.Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial..Lancet Oncol2012;13:239-46

[5] Soria JC,Vansteenkiste J,Chewaskulyong B.Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer..N Engl J Med2018;378:113-25

[6] Chaib I,Pilotto S,Cai X.Co-activation of STAT3 and YES-associated protein 1 (YAP1) pathway in EGFR-mutant NSCLC..J Natl Cancer Inst2017;109: PMCID:PMC5409000

[7] Codony-Servat C,Karachaliou N,Chaib I.Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC)..Oncotarget2017;8:47305-16 PMCID:PMC5564566

[8] Karachaliou N,Cardona AF,Bracht JWP.Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell lung cancer associated with poor prognosis..EBioMedicine2018;29:112-27 PMCID:PMC5925453

[9] Gao SP,Leslie K,Motoi N.Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas..J Clin Invest2007;117:3846-56 PMCID:PMC2096430

[10] Fan W,Yin L,Hafez-Khayyata S.MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents..Cancer Res2011;71:4494-505 PMCID:PMC3132557

[11] Lee HJ,Cao Y,Kim HJ.Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells..Cancer Cell2014;26:207-21

[12] Zhong Z,Darnell JE Jr.Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6..Science1994;264:95-8

[13] Nan J,Chen X,Wang Y.TPCA-1 is a direct dual inhibitor of STAT3 and NF-kappaB and regresses mutant EGFR-associated human non-small cell lung cancers..Mol Cancer Ther2014;13:617-29

[14] Tursynbay Y,Li Z,Zhumadilov Z.Pim-1 kinase as cancer drug target: An update..Biomed Rep2016;4:140-6 PMCID:PMC4734217

[15] Casillas AL,Sainz AG,Desai AA.Hypoxia-Inducible PIM kinase expression promotes resistance to antiangiogenic agents..Clin Cancer Res2018;24:169-80 PMCID:PMC6214353

[16] Cen B,Wang W.Elevation of receptor tyrosine kinases by small molecule AKT inhibitors in prostate cancer is mediated by Pim-1..Cancer Res2013;73:3402-11 PMCID:PMC3680595

[17] Zhang M,Sun H,Zhang Q.Pim1 supports human colorectal cancer growth during glucose deprivation by enhancing the Warburg effect..Cancer Science2018;109:1468-79 PMCID:PMC5980151

[18] Weirauch U,Thomas M,Huber K.Functional role and therapeutic potential of the Pim-1 kinase in colon carcinoma..Neoplasia2013;15:783-94 PMCID:PMC3689241

[19] Liu K,Wang Q,Zhang B.Hispidulin suppresses cell growth and metastasis by targeting PIM1 through JAK2/STAT3 signaling in colorectal cancer..Cancer Sci2018;109:1369-81 PMCID:PMC5980372

[20] Braso-Maristany F,Catchpole S,Quist J.PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer..Nat Med2016;22:1303-13 PMCID:PMC5552044

[21] Zhao W,Li P.PIM1: a promising target in patients with triple-negative breast cancer..Med Oncol2017;34:142

[22] Keane NA,Natoni A,O’Dwyer M.Targeting the Pim kinases in multiple myeloma..Blood Cancer J2015;5:e325 PMCID:PMC4526774

[23] Koblish H,Shin N,Wang Q.Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies..PLoS One2018;13:e0199108 PMCID:PMC6013247

[24] Kuo HP,Hsieh S,Cheung LW.The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma..Am J Cancer Res2016;6:2489-501 PMCID:PMC5126268

[25] Brunen D,Lieftink C,Bernards R.PIM kinases are a potential prognostic biomarker and therapeutic target in neuroblastoma..Mol Cancer Ther2018;17:849-57

[26] An N,LaRue AC,Cen B.Activation of Pim kinases is sufficient to promote resistance to MET small-molecule inhibitors..Cancer Res2015;75:5318-28 PMCID:PMC4683614

[27] Warfel NA,Song JH.PIM kinase inhibitors kill hypoxic tumor cells by reducing Nrf2 signaling and increasing reactive oxygen species..Mol Cancer Ther2016;15:1637-47 PMCID:PMC4936950

[28] Jin B,Wu CL,Chen H.PIM-1 modulates cellular senescence and links IL-6 signaling to heterochromatin formation..Aging Cell2014;13:879-89 PMCID:PMC4331745

[29] Liu J,Shao L,Yu X.Pim-3 enhances melanoma cell migration and invasion by promoting STAT3 phosphorylation..Cancer Biol Ther2018;19:160-8 PMCID:PMC5790343

[30] Lee M,Min A,Kim S.Pan-Pim kinase inhibitor AZD1208 suppresses tumor growth and synergistically interacts with akt inhibition in gastric cancer cells..Cancer Res Treat2018;

[31] Cen B,Song JH,DuPont R.The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signaling..Mol Cell Biol2014;34:2517-32 PMCID:PMC4054323

[32] Chou TC.Drug combination studies and their synergy quantification using the Chou-Talalay method..Cancer Res2010;70:440-6

[33] Narayan RS,Brands E,Stalpers LJ.The allosteric AKT inhibitor MK2206 shows a synergistic interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures..BMC Cancer2017;17:204 PMCID:PMC5359921

[34] Karachaliou N,Bracht JWP,Drozdowskyj A.Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC)..EBioMedicine2019;39:207-14 PMCID:PMC6354556

[35] Ettinger DS,Wood DE,Bauman J.NCCN guidelines insights: non-small cell lung cancer, version 5.2018..J Natl Compr Canc Netw2018;16:807-21

[36] Raab MS,Thomas SK,Goh YT.Phase 1 study update of the novel pan-pim kinase inhibitor LGH447 in patients with relapsed/refractory multiple myeloma..Blood2014;

[37] Paino T,Gonzalez-Mendez L,Hernandez-Garcia S.The novel Pan-PIM kinase inhibitor, PIM447, displays dual antimyeloma and bone-protective effects, and potently synergizes with current standards of care..Clin Cancer Res2017;23:225-38

[38] Langowski JL,Burger M,Zavorotinskaya T.The Pan-PIM kinase inhibitor LGH447 shows activity in PIM2-dependent multiple myeloma and in AML models..Blood2013;122:1666